Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Preparation and in vitro Studies of [125-I]IUDR-T101 Antibody Conjugate



M C. Chakrabarti, C H. Paik, J A. Carrasquillo


Idoxuridine labeled with 125I was conjugated to polylysine. This conjugate was then coupled to the carbohydrate side chains of T101 monoclonal antibodiy (anti-CD5). The immunoreactivity, cell retention, cytotoxicity, and intracellular localization of this conjugate was tested in CCRF-CEM cells (CD5 positive). The conjugate had 68 % immunoreactivity. The retention of 125I by CCRF-CEM cells was higher for the conjugate than for T101 directly labeled with 125I and more of it localized in the nucleus than did the 125I-labeled T101. The 125I IUDR-polylysine-T101 conjugate was more cytotoxic than the 125I-labeled T101. In conclusion, the conjugation of [125I]IUDR to T101 is feasible, and preferential targeting of the 125I to the nucleus is obtained.
Cancer Biotherapy and Radiopharmaceuticals
No. 2


CD5, endocytosis, iodine, IUDR, monoclonal antibody


Chakrabarti, M. , Paik, C. and Carrasquillo, J. (2000), Preparation and in vitro Studies of [<sup>125</sup>-I]IUDR-T101 Antibody Conjugate, Cancer Biotherapy and Radiopharmaceuticals (Accessed December 5, 2023)
Created January 1, 2000, Updated February 17, 2017